Rotigaptide
Also known as: AAP10 analogue, antiarrhythmic peptide analogue, Rotigaptide, ZP123
Source Rotigaptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Rotigaptide (ZP123) is a synthetic peptide that targets connexin 43 to improve cardiac gap junction function, investigated for treatment of atrial fibrillation and other arrhythmias.
Mechanism of Action
Enhances gap junction intercellular communication by modulating connexin 43 phosphorylation and channel conductance
Routes of Administration
Goals & Uses
- Prevention of atrial fibrillationCardiovascular / AntiarrhythmicModerate
- Cardioprotection during ischemiaCardiovascular / CardioprotectionLow
- Post‑myocardial infarction ventricular arrhythmia reductionArrhythmiaLow
- Prevention of ventricular arrhythmiasCardiovascular / AntiarrhythmicModerate
- Atrial fibrillation managementArrhythmiaModerate
Contraindications
- Hypersensitivity to rotigaptide or peptide excipientsAllergicHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypotensionCardiovascularRareLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Antiarrhythmic agentsModerate
- Concomitant anti‑arrhythmic drugsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- PediatricsAgeRelative
Regulatory Status
- European UnionInvestigationalUnder clinical development
- United StatesInvestigationalInvestigational New Drug application filed
- United KingdomInvestigationalClinical trials ongoing
Rotigaptide has not received regulatory approval in any jurisdiction. Clinical development appears to have stalled after Phase I/II studies. It remains a research/investigational compound.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Rotigaptide?
Rotigaptide (ZP123) is a synthetic peptide that targets connexin 43 to improve cardiac gap junction function, investigated for treatment of atrial fibrillation and other arrhythmias.
What is Rotigaptide used for?
Rotigaptide is educationally associated with: Prevention of atrial fibrillation, Cardioprotection during ischemia, Post‑myocardial infarction ventricular arrhythmia reduction, Prevention of ventricular arrhythmias, Atrial fibrillation management. Educational only — not medical advice.
How is Rotigaptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Rotigaptide?
Reported adverse effects include: Injection site reactions, Injection site pain, Headache, Hypotension, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Rotigaptide?
Recorded contraindications: Hypersensitivity to rotigaptide or peptide excipients. Consult a qualified clinician before use.